Market Research Report
Febrile Neutropenia - Pipeline Review, H2 2016
|Published by||Global Markets Direct||Product code||251568|
|Published||Content info||60 Pages
Delivery time: 1-2 business days
|Febrile Neutropenia - Pipeline Review, H2 2016|
|Published: October 26, 2016||Content info: 60 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides an overview of the Febrile Neutropenia (Hematological Disorders) pipeline landscape.
Febrile neutropenia can develop in any form of neutropenia, but is most generally recognized as a complication of chemotherapy when it is myelosuppressive (suppresses the bone marrow from producing blood cells). Symptoms include fever, flu-like symptoms, shaking chills, severe night sweats, nausea and vomiting, especially with fever, tenderness, redness, swelling, pain or discharge at the site of a catheter and headache or neck stiffness.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Febrile Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Febrile Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Febrile Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 1, 2, 2, 1 and 3 respectively for Febrile Neutropenia.
Febrile Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.